메뉴 건너뛰기




Volumn 21, Issue 1, 2014, Pages

Redefining cancer: A new paradigm for better and faster treatment innovation

Author keywords

Cancer treatment; Clinical trials; Genomic variation; Innovation; Orphan drugs; Resistance

Indexed keywords

ORPHAN DRUG; ANTINEOPLASTIC AGENT;

EID: 84895791097     PISSN: 17106222     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (9)

References (29)
  • 3
    • 84876096711 scopus 로고    scopus 로고
    • Fool's gold, lost treasures, and the randomized clinical trial
    • Stewart DJ, Kurzrock R. Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer 2013;13:193.
    • (2013) BMC Cancer , vol.13 , pp. 193
    • Stewart, D.J.1    Kurzrock, R.2
  • 4
    • 78349287749 scopus 로고    scopus 로고
    • A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies
    • Cheng SK, Dietrich MS, Dilts DM. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin Cancer Res 2010;16:5557-63.
    • (2010) Clin Cancer Res , vol.16 , pp. 5557-5563
    • Cheng, S.K.1    Dietrich, M.S.2    Dilts, D.M.3
  • 6
    • 84875360328 scopus 로고    scopus 로고
    • Experimental designs for small randomised clinical trials: An algorithm for choice
    • Cornu C, Kassai B, Fisch R, et al. Experimental designs for small randomised clinical trials: an algorithm for choice. Orphanet Journal of Rare Diseases 2013;8:48.
    • (2013) Orphanet Journal of Rare Diseases , vol.8 , pp. 48
    • Cornu, C.1    Kassai, B.2    Fisch, R.3
  • 7
    • 84881482075 scopus 로고    scopus 로고
    • Sustainable rare diseases business and drug access: No time for misconceptions
    • Rollet P, Lemoine A, Dunoyer M. Sustainable rare diseases business and drug access: no time for misconceptions. Orphanet Journal of Rare Diseases 2013;8:109.
    • (2013) Orphanet Journal of Rare Diseases , vol.8 , pp. 109
    • Rollet, P.1    Lemoine, A.2    Dunoyer, M.3
  • 8
    • 79958036418 scopus 로고    scopus 로고
    • Characteristics of clinical trials to support approval of orphan vs. nonorphan drugs for cancer
    • Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs. nonorphan drugs for cancer. JAMA 2011;305:2320-6.
    • (2011) JAMA , vol.305 , pp. 2320-2326
    • Kesselheim, A.S.1    Myers, J.A.2    Avorn, J.3
  • 9
    • 84882953749 scopus 로고    scopus 로고
    • Developing standards for breakthrough therapy designation in oncology
    • Horning SJ, Haber DA, Selig WK, et al. Developing standards for breakthrough therapy designation in oncology. Clin Cancer Res 2013;19:4297-304.
    • (2013) Clin Cancer Res , vol.19 , pp. 4297-4304
    • Horning, S.J.1    Haber, D.A.2    Selig, W.K.3
  • 10
    • 84895800854 scopus 로고    scopus 로고
    • Clinical trials in rare disorders: Considering a toolkit for developing evidence based treatment
    • Abrahamyan L, Diamond IR, Johnson SR, Feldman BM. Clinical trials in rare disorders: Considering a toolkit for developing evidence based treatment. J Popul Ther Clin Pharmacol 2014;Vol 21(1):e66-e78.
    • (2014) J Popul Ther Clin Pharmacol , vol.21 , Issue.1
    • Abrahamyan, L.1    Diamond, I.R.2    Johnson, S.R.3    Feldman, B.M.4
  • 11
    • 34248204234 scopus 로고    scopus 로고
    • Uncommon tumors and exceptional therapies: Paradox or paradigm?
    • Braiteh F, Kurzrock R. Uncommon tumors and exceptional therapies: paradox or paradigm? Mol Cancer Ther 2007;6:1175-9.
    • (2007) Mol Cancer Ther , vol.6 , pp. 1175-1179
    • Braiteh, F.1    Kurzrock, R.2
  • 13
    • 84882576021 scopus 로고    scopus 로고
    • CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma
    • Matsuura S, Shinmura K, Kamo T, et al. CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma. Oncology Reports 2013;30:1675-80.
    • (2013) Oncology Reports , vol.30 , pp. 1675-1680
    • Matsuura, S.1    Shinmura, K.2    Kamo, T.3
  • 14
    • 84881663252 scopus 로고    scopus 로고
    • KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung
    • Borrelli N, Giannini R, Proietti A, et al. KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung. Lung Cancer 2013;81:377-81.
    • (2013) Lung Cancer , vol.81 , pp. 377-381
    • Borrelli, N.1    Giannini, R.2    Proietti, A.3
  • 15
    • 33750072289 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer
    • Ahmed SM, Salgia R. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology 2006;11:687-92.
    • (2006) Respirology , vol.11 , pp. 687-692
    • Ahmed, S.M.1    Salgia, R.2
  • 16
    • 79953118839 scopus 로고    scopus 로고
    • Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
    • Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science Translational Medicine 2011;3:75ra26.
    • (2011) Science Translational Medicine , vol.3
    • Sequist, L.V.1    Waltman, B.A.2    Dias-Santagata, D.3
  • 18
    • 70350135946 scopus 로고    scopus 로고
    • Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development
    • Vidaurre T, Wilkerson J, Simon R, Bates SE, Fojo T. Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development. Cancer J 2009;15:366-73.
    • (2009) Cancer J , vol.15 , pp. 366-373
    • Vidaurre, T.1    Wilkerson, J.2    Simon, R.3    Bates, S.E.4    Fojo, T.5
  • 21
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
    • (2011) N Engl J Med , vol.364 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 23
    • 84878066430 scopus 로고    scopus 로고
    • Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer
    • Coffee EM, Faber AC, Roper J, et al. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res 2013;19:2688-98.
    • (2013) Clin Cancer Res , vol.19 , pp. 2688-2698
    • Coffee, E.M.1    Faber, A.C.2    Roper, J.3
  • 25
    • 79956318148 scopus 로고    scopus 로고
    • Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer
    • Mino-Kenudson M, Mark EJ. Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. Archives of Pathology & Laboratory Medicine 2011;135:655-64.
    • (2011) Archives of Pathology & Laboratory Medicine , vol.135 , pp. 655-664
    • Mino-Kenudson, M.1    Mark, E.J.2
  • 27
    • 0032748041 scopus 로고    scopus 로고
    • Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics
    • Newell DR, Burtles SS, Fox BW, Jodrell DI, Connors TA. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Br J Cancer 1999;81:760-8.
    • (1999) Br J Cancer , vol.81 , pp. 760-768
    • Newell, D.R.1    Burtles, S.S.2    Fox, B.W.3    Jodrell, D.I.4    Connors, T.A.5
  • 28
    • 1942518871 scopus 로고    scopus 로고
    • The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies
    • Newell DR, Silvester J, McDowell C, Burtles SS. The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies. Eur J Cancer 2004;40:899-906.
    • (2004) Eur J Cancer , vol.40 , pp. 899-906
    • Newell, D.R.1    Silvester, J.2    McDowell, C.3    Burtles, S.S.4
  • 29
    • 0035683744 scopus 로고    scopus 로고
    • The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute: Industry collaborations in new agent development
    • Ansher SS, Scharf R. The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute: Industry collaborations in new agent development. Annals of the New York Academy of Sciences 2001;949:333-40.
    • (2001) Annals of the New York Academy of Sciences , vol.949 , pp. 333-340
    • Ansher, S.S.1    Scharf, R.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.